A Phase 1 Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APN1125 in Healthy Normal Subjects
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2016
At a glance
- Drugs APN 1125 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors CoMentis
- 07 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov.
- 25 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.